| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 07/06/2024 | 07:00 | GlobeNewswire Inc. | Ipsen et Marengo Therapeutics annoncent la conclusion d’un second partenariat stratégique afin de faire progresser les actifs « T-Cell Engager » de précision de la plateforme TriSTAR de Marengo | EU:IPN | Ipsen SA |
| 07/06/2024 | 07:00 | GlobeNewswire Inc. | Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform | EU:IPN | Ipsen SA |
| 06/06/2024 | 18:00 | GlobeNewswire Inc. | Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social | EU:IPN | Ipsen SA |
| 06/06/2024 | 18:00 | GlobeNewswire Inc. | Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital | EU:IPN | Ipsen SA |
| 06/06/2024 | 14:30 | GlobeNewswire Inc. | Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer | EU:IPN | Ipsen SA |
| 06/06/2024 | 14:30 | GlobeNewswire Inc. | Ipsen nomme Josep Catllà, en qualité de Vice-Président Exécutif, Chief Corporate Affairs Officer | EU:IPN | Ipsen SA |
| 05/06/2024 | 08:00 | GlobeNewswire Inc. | Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis | EU:IPN | Ipsen SA |
| 03/06/2024 | 07:00 | GlobeNewswire Inc. | Ipsen initiates a share buy-back program to cover its free employee share-allocation plan | EU:IPN | Ipsen SA |
| 03/06/2024 | 07:00 | GlobeNewswire Inc. | Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés | EU:IPN | Ipsen SA |
| 30/05/2024 | 18:15 | GlobeNewswire Inc. | Ipsen annonce le lancement d'une opération d’actionnariat salarié | EU:IPN | Ipsen SA |
| 30/05/2024 | 18:15 | GlobeNewswire Inc. | Ipsen announces the launch of an employee shareholding plan | EU:IPN | Ipsen SA |
| 28/05/2024 | 18:00 | GlobeNewswire Inc. | Assemblée Générale Annuelle d’Ipsen S.A. du 28 mai 2024 | EU:IPN | Ipsen SA |
| 28/05/2024 | 18:00 | GlobeNewswire Inc. | Annual General Meeting of Ipsen S.A. held on 28 May 2024 | EU:IPN | Ipsen SA |
| 28/05/2024 | 07:00 | GlobeNewswire Inc. | Descriptif du cadre réglementaire du programme de rachat d’actions soumis par le Conseil d’administration à l’approbation de l’Assemblée Générale Annuelle des actionnaires d’Ipsen S.A. du 28 mai 2024 | EU:IPN | Ipsen SA |
| 28/05/2024 | 07:00 | GlobeNewswire Inc. | Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024 | EU:IPN | Ipsen SA |
| 07/05/2024 | 14:55 | GlobeNewswire Inc. | IPSEN SA. - Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 28 mai 2024 | EU:IPN | Ipsen SA |
| 07/05/2024 | 14:55 | GlobeNewswire Inc. | Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting | EU:IPN | Ipsen SA |
| 02/05/2024 | 07:30 | GlobeNewswire Inc. | Ipsen appoints Keira Driansky as EVP, President of North America | EU:IPN | Ipsen SA |
| 02/05/2024 | 07:30 | GlobeNewswire Inc. | Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord | EU:IPN | Ipsen SA |
| 24/04/2024 | 07:00 | GlobeNewswire Inc. | Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024 | EU:IPN | Ipsen SA |
| 24/04/2024 | 07:00 | GlobeNewswire Inc. | Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance | EU:IPN | Ipsen SA |
| 22/04/2024 | 07:00 | GlobeNewswire Inc. | Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases | EU:IPN | Ipsen SA |
| 22/04/2024 | 07:00 | GlobeNewswire Inc. | Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares | EU:IPN | Ipsen SA |
| 17/04/2024 | 18:00 | GlobeNewswire Inc. | Ipsen publie son Document d’enregistrement universel 2023 | EU:IPN | Ipsen SA |
| 17/04/2024 | 18:00 | GlobeNewswire Inc. | Ipsen publishes its 2023 Universal Registration Document | EU:IPN | Ipsen SA |
| 02/04/2024 | 07:00 | GlobeNewswire Inc. | Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors | EU:IPN | Ipsen SA |
| 02/04/2024 | 07:00 | GlobeNewswire Inc. | Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides | EU:IPN | Ipsen SA |
| 15/02/2024 | 10:00 | GlobeNewswire Inc. | Ipsen S.A. publie ses comptes consolidés 2023 | EU:IPN | Ipsen SA |
| 15/02/2024 | 10:00 | GlobeNewswire Inc. | Ipsen S.A. publishes its 2023 Consolidated Financial Statements | EU:IPN | Ipsen SA |
| 13/02/2024 | 22:08 | GlobeNewswire Inc. | Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA | EU:IPN | Ipsen SA |